Stay current with the latest press releases from within the industry.
Release issued 18th February 2002
Embil Pharmaceutical Co. Ltd. announced today, reports from two new Clinical Studies of Neo-Penotran Forte have been accepted for presentation at the 10'th International Congress on Infectious Diseases (ICID) meeting to be held in Singapore between the dates of 11-14 March 2002.
The titles of the two presentations are as follows:
1. Efficacy of Once Daily, 7-day Treatment with Neo- Penotran Forte - A Triple-active Pessary for the Treatment of Single and Mixed Vaginal Infections.
2. Tolerance, Acceptability and Absorption Study of Neo- Penotran Forte-L and Neo-Penotran Forte Pessaries in Healthy Volunteers.
Each dose of Neo-Penotran® Forte contains 750 mg metronidazole and 200 mg miconazole nitrate in therapeutic concentrations for the local treatment of the three main types of vaginal infections and mixed forms of vaginitis. The dose is applied once daily for a 7 day treatment
Each dose of Neo-Penotran® Forte-L contains 750 mg metronidazole and 200 mg miconazole nitrate plus 100 mg lidocaine. The dose is applied once daily for a 7 day treatment. The presence of lidocaine serves to reduce pain caused by irritation and inflammation due to vaginitis, sometimes more acute during the first 3 days of treatment.
Both ingredients of Neo-Penotran®, metronidazole and miconazole nitrate, have been established as first line treatment of vaginal candidiasis, bacterial and trichomonal vaginitis.
These new studies form the basis of the high clinical success of the FORTE version of this unique triple active vaginal product. The use of Neo-Penotran Forte has the added benefit of better patient compliance and ease of usage with once daily dosing.
If you want to find out more about the company visit Embil Pharmaceutical Co. Ltd. profile.
(17th November 2004) Sulidin® 1% Nimesulide LPS® gel receives European and US Patents
(10th October 2002) Recent Patent Approvals for SULIDIN® LPS® (Topical Nimesulide Gel)
Clients in focus...